Britannia Life Sciences Inc News Releases

Britannia Life Sciences Announces $5.3 Million Acquisition of Commercial Equipment Loan Portfolio

Fri, 12 Jun 2026 07:30:00 -0400

Performing Portfolio Acquired at a Discount Reflects Continued Progress in the Company's Asset-Backed Lending Strategy; Company Expects to Generate in Excess of $2 Million in Free Cash Flow Over the Coming Twelve Months Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) (the "Company" or "Britannia") is pleased to announce that it has completed a strategic investment of approximately $5.3 million in a portfolio of performing commercial equipment loans...

Britannia Life Sciences Provides Corporate Update

Thu, 21 May 2026 09:08:00 -0400

Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations Toronto, Ontario--(Newsfile Corp. - May 21, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today provides a corporate update on its current asset position, strategic direction, and capital markets initiatives. The Board of Directors has approved a refined corporate strategy which repositions Britannia as a public market "venture builder...

Britannia Life Sciences Inc. Enters into $11.3 Million Share Exchange Agreement with McEwen Inc. and Britannia Mining Solutions Inc.

Mon, 03 Nov 2025 07:07:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has entered into a share exchange agreement (the "Agreement") with McEwen Inc. ("McEwen") and Britannia Mining Solutions Inc. (doing business as Paragon Geochemical Laboratories Inc.) (together, "Paragon").Pursuant to the terms of the Agreement, McEwen will acquire 648,002 common shares of Paragon from Britannia at a deemed price of $17.50...

Britannia Life Sciences Inc. Delays Closing of Debenture Offering

Fri, 19 Sep 2025 17:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") announced today that the closing of its previously announced non-brokered private placement offering of unsecured debentures (the "Debentures") for gross proceeds of up to CAD$10 million (the "Offering") will be delayed until September 30, 2025 or such other date as the Company and subscribers may agree. The Offering was initially expected to close on or before...

Britannia Life Sciences Inc. Announces $10 Million Debenture Offering to Provide Investor Access to Asset-Backed Loan Portfolio

Mon, 28 Jul 2025 08:46:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce the launch of a non-brokered private placement offering of unsecured debentures (the "Debentures") for gross proceeds of up to $10 million CAD.The proceeds from the offering will be used to provide debenture holders of Britannia with exposure to a fixed return generated by a portfolio of asset-backed loans, offering strong underlying collateral...

Britannia Life Sciences Provides a Corporate Update

Tue, 08 Jul 2025 08:30:00 -0400

$5mm treasury investment in asset backed loansLooking to leverage royalty and private debt opportunitiesParagon Advanced Labs progresses towards listingToronto, Ontario--(Newsfile Corp. - July 8, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to announce that it has committed $5 million of its treasury capital, generated from the sale of its former UK operating subsidiary, into an arm's length portfolio of asset-backed loans (the "Investment"). The...

Britannia Life Sciences Inc. Provides Corporate Update

Tue, 28 Jan 2025 16:10:00 -0500

Toronto, Ontario--(Newsfile Corp. - January 28, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") is pleased to provide the following corporate update to its shareholders:Sale of UK Operating SubsidiaryAs announced recently, Britannia successfully completed the sale of Advanced Development and Safety Laboratories Inc. ("ADSL"), its UK operating subsidiary (the "Transaction"). Net proceeds from the Transaction, after settling debt, intercompany loans, and minority...

Britannia Life Sciences Announces Strategic Divestiture of UK Operating Subsidiary

Thu, 09 Jan 2025 08:30:00 -0500

Britannia selling its UK lab and testing business to a private UK-based acquiror for total enterprise value of up to £24.2 million (CAD$43.6 million)Initial consideration of £18.7 million (CAD$33.7 million) payable in cash on closingAdditional consideration of up to £5.5 million (CAD$9.9 million) payable contingent on achieving certain EBITDA targets at March 2025 and December 2025.After the disposition Britannia will be debt free with assets that consist of significant cash reserves, and shares...

Britannia Life Sciences Inc. Announces Results of Annual Meeting of Shareholders

Thu, 14 Nov 2024 16:30:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 14, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders held on November 12, 2024, in Toronto (the "Meeting").All matters presented for approval at the Meeting were duly authorized and approved, as follows:Electing each of Scott Secord, Peter Shippen and Greg Taylor as directors of the Company to hold office for the...

Britannia Launches Financing to Support Britannia Mining Solutions Lab Rollout

Thu, 10 Oct 2024 20:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today announced a financing initiative (the "Financing") to fund the continued growth and expansion of its partially owned subsidiary, Britannia Mining Solutions Inc. ("BMS"). BMS specializes in providing innovative and efficient assay and geochemical services to the mining sector, with a particular focus on utilizing cutting-edge technologies such as PhotonAssay™ to...